Tags

Type your tag names separated by a space and hit enter

CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
J Surg Oncol. 2007 Feb 01; 95(2):142-7.JS

Abstract

BACKGROUND AND OBJECTIVES

In this study, the value of the serum tumor markers carcinoembryonic antigen (CEA), CA 19-9, and CA 125 was assessed in the differential diagnosis of benign and malignant pancreatic diseases with and without obstructive jaundice.

METHODS

Serum levels of CEA, CA 19-9, and CA 125 were measured by immunoradiometric assay before the treatment in 123 patients with pancreatic carcinoma and 58 patients with a benign pancreatic disease.

RESULTS

The sensitivity of CEA, CA 19-9, and CA 125 in the diagnosis of pancreatic carcinoma was 39.0%, 81.3%, and 56.9%; and specificity was 91.4%, 75.9%, and 77.6%, respectively. Although there was no significant difference between the CA 19-9 positivity ratios of the jaundiced (84.3%) and nonjaundiced (73.5%) patient subgroups of the pancreatic carcinoma, this ratio was significantly higher in the jaundiced subgroup (64.7%) than the nonjaundiced subgroup (7.3%) of the benign pancreatic diseases (P < 0.001). The CEA and CA 125 positivity ratios of jaundiced and nonjaundiced subgroups of patients with benign and malignant pancreatic diseases were not significantly different.

CONCLUSIONS

In the differential diagnosis of pancreatic carcinoma from benign pancreatic diseases, CA 19-9 can be useful in the nonjaundiced patients, whereas CA 125 provides a limited contribution in jaundiced patients.

Authors+Show Affiliations

Fifth Department of Surgery, SSK Okmeydani Training Hospital, Istanbul, Turkey. nduraker@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17262731

Citation

Duraker, Nüvit, et al. "CEA, CA 19-9, and CA 125 in the Differential Diagnosis of Benign and Malignant Pancreatic Diseases With or Without Jaundice." Journal of Surgical Oncology, vol. 95, no. 2, 2007, pp. 142-7.
Duraker N, Hot S, Polat Y, et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95(2):142-7.
Duraker, N., Hot, S., Polat, Y., Höbek, A., Gençler, N., & Urhan, N. (2007). CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. Journal of Surgical Oncology, 95(2), 142-7.
Duraker N, et al. CEA, CA 19-9, and CA 125 in the Differential Diagnosis of Benign and Malignant Pancreatic Diseases With or Without Jaundice. J Surg Oncol. 2007 Feb 1;95(2):142-7. PubMed PMID: 17262731.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. AU - Duraker,Nüvit, AU - Hot,Semih, AU - Polat,Yücel, AU - Höbek,Anil, AU - Gençler,Nur, AU - Urhan,Nuray, PY - 2007/1/31/pubmed PY - 2007/2/24/medline PY - 2007/1/31/entrez SP - 142 EP - 7 JF - Journal of surgical oncology JO - J Surg Oncol VL - 95 IS - 2 N2 - BACKGROUND AND OBJECTIVES: In this study, the value of the serum tumor markers carcinoembryonic antigen (CEA), CA 19-9, and CA 125 was assessed in the differential diagnosis of benign and malignant pancreatic diseases with and without obstructive jaundice. METHODS: Serum levels of CEA, CA 19-9, and CA 125 were measured by immunoradiometric assay before the treatment in 123 patients with pancreatic carcinoma and 58 patients with a benign pancreatic disease. RESULTS: The sensitivity of CEA, CA 19-9, and CA 125 in the diagnosis of pancreatic carcinoma was 39.0%, 81.3%, and 56.9%; and specificity was 91.4%, 75.9%, and 77.6%, respectively. Although there was no significant difference between the CA 19-9 positivity ratios of the jaundiced (84.3%) and nonjaundiced (73.5%) patient subgroups of the pancreatic carcinoma, this ratio was significantly higher in the jaundiced subgroup (64.7%) than the nonjaundiced subgroup (7.3%) of the benign pancreatic diseases (P < 0.001). The CEA and CA 125 positivity ratios of jaundiced and nonjaundiced subgroups of patients with benign and malignant pancreatic diseases were not significantly different. CONCLUSIONS: In the differential diagnosis of pancreatic carcinoma from benign pancreatic diseases, CA 19-9 can be useful in the nonjaundiced patients, whereas CA 125 provides a limited contribution in jaundiced patients. SN - 0022-4790 UR - https://www.unboundmedicine.com/medline/citation/17262731/CEA_CA_19_9_and_CA_125_in_the_differential_diagnosis_of_benign_and_malignant_pancreatic_diseases_with_or_without_jaundice_ L2 - https://doi.org/10.1002/jso.20604 DB - PRIME DP - Unbound Medicine ER -